[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 9 of about 9
1. DeMonaco NA, Jacobs SA: Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan. Clin Nucl Med; 2007 Dec;32(12):933-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum sickness in a patient with follicular lymphoma after rituximab and radioimmunotherapy with ibritumomab tiuxetan.
  • A previously healthy 47-year-old woman was treated for follicular lymphoma, grade III, with cyclophosphamide, adriamycin, vincristine, prednisone with rituximab (CHOP-R) followed by ibritumomab tiuxetan and rituximab.
  • She developed a serum sickness-like illness during immunotherapy with fever, myalgias, arthralgias, and pleural and pericardial effusions.
  • Despite anti-inflammatory therapies her symptoms persisted for 10 months before ultimate resolution.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Lymphoma, Follicular / radiotherapy. Radioimmunotherapy / adverse effects. Serum Sickness / etiology
  • [MeSH-minor] Anti-Inflammatory Agents / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Blood Sedimentation / drug effects. C-Reactive Protein / biosynthesis. C-Reactive Protein / drug effects. Combined Modality Therapy / adverse effects. Female. Humans. Indomethacin / therapeutic use. Middle Aged. Prednisone / therapeutic use. Rituximab. Spleen / pathology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. INDOMETHACIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18030044.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / ibritumomab tiuxetan; 4F4X42SYQ6 / Rituximab; 9007-41-4 / C-Reactive Protein; VB0R961HZT / Prednisone; XXE1CET956 / Indomethacin
  •  go-up   go-down


2. Ganguly S, Divine CL, Deauna-Limayo D, Bodensteiner DC, Cook JD, Lewis JN, Skikne BS: Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. Ann Hematol; 2005 Aug;84(8):526-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response.
  • The best treatment option for patients with relapsed or high-grade follicular lymphoma (FL) is unknown.
  • In spite of major advances in the therapy for FL, disease-free survival remains short, and median time to progression is just over a year.
  • Autologous stem cell transplantation in patients with relapsed FL is safe and appears to improve disease-free survival.
  • In an attempt to examine whether autologous stem cell transplantation provides long-term disease control in patients with relapsed or high-grade FL, we retrospectively evaluated our experience and analyzed the outcomes of autologous stem cell transplantation in patients with FL from 1991 to 2003.
  • Twenty-one patients were salvaged after relapse with second-line chemotherapy.
  • Of these, 14 were in CR at the time of transplantation, and seven patients were transplanted with active disease.
  • Median time for neutrophil recovery was 11.5 days (range 9-35 days) and 15 days (range 10-40 days) for platelets.
  • Overall survival (OS) and disease-free survival (DFS) of all evaluable patients were 71.6 and 40%, respectively.
  • For those transplanted with disease, a complete response was achieved in 43% of patients, with the OS and DFS of 57 and 19%, respectively.
  • Disease status at transplantation was not a significant variable for survival (p>0.3).
  • Three patients developed moderate to severe treatment-related toxicity, two with grade III mucositis and one with life-threatening infection.
  • When these results are compared with historical controls or patients treated with other modalities, autologous stem cell transplantation appears to be providing the longest disease-free survival and best duration of response.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Follicular / therapy
  • [MeSH-minor] Adult. Bone Marrow Transplantation / methods. Bone Marrow Transplantation / mortality. Disease-Free Survival. Female. Graft Survival. Humans. Kinetics. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation / methods. Peripheral Blood Stem Cell Transplantation / mortality. Retrospective Studies. Salvage Therapy / methods. Survival Analysis. Transplantation, Autologous


3. Santini G, Chisesi T, Nati S, Porcellini A, Zoli V, Rizzoli V, Zupo S, Marino G, Rubagotti A, Polacco A, Spriano M, Vimercati R, Congiu AM, Ravetti JL, Aversa S, Candela M, Patti C: Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group. Leuk Lymphoma; 2004 Jun;45(6):1141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine, cyclophosphamide and mitoxantrone for untreated follicular lymphoma: a report from the non-Hodgkin's lymphoma co-operative study group.
  • The aim of the study was to determine the safety and efficacy of the combination of fludarabine (FLU), cyclophosphamide (CY) and mitoxantrone (FLU/CY/MITO) in untreated follicular lymphomas (FL), Sixty patients with newly diagnosed stage II bulky to IV FL, median age 59 years (range 36-70), received FLU/CY/MITO regimen (FLU 25 mg/m2 days 1-3, CY 300 mg/m2 days 1-3, Mito 10 mg/m2 day 1).
  • Patients received antibiotic oral prophylaxis during all treatments, and growth factors (G-CSF) when grade III granulocytopenia (WHO) occurred.
  • The overall response rate was 87%: 46 patients achieved complete response (CR) (77%), 6 a partial response (10%) and 8 were non-responders.
  • Fifty patients are surviving with a median observation time of 31 months.
  • Sixty percent of patients experienced grade III-IV granulocytopenia.
  • Two patients suffered grade III pulmonary infection and one grade III liver toxicity.
  • At the end of treatment, 25 of these patients had CR and 19 (76%) converted to polymerase chain reaction (PCR) negativity.
  • FLU/CY/MITO regimen showed a high level of activity in follicular lymphoma.
  • Toxicity, mainly hematological, was acceptable and the treatment was made feasible by the use of antibiotic prophylaxis and G-CSF.
  • Significant non-hematological toxicities were seen, but no patients died.
  • The conversion of bcl-2 from positive to negative by PCR in BM and/or PB suggests a possible role for this treatment in clearing minimal residual disease and improving patients' outcome.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Bone Marrow. Cyclophosphamide / administration & dosage. Disease-Free Survival. Female. Humans. Male. Middle Aged. Mitoxantrone / administration & dosage. Neoplasm, Residual / drug therapy. Protein Transport. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Safety. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15359993.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2; 8N3DW7272P / Cyclophosphamide; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


Advertisement
4. Dursun P, Gultekin M, Bozdag G, Usubutun A, Uner A, Celik NY, Yuce K, Ayhan A: Primary cervical lymphoma: report of two cases and review of the literature. Gynecol Oncol; 2005 Sep;98(3):484-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cervical lymphoma: report of two cases and review of the literature.
  • BACKGROUND: Primary lymphoma arising from the female genital tract has been rarely encountered.
  • Primary cervical lymphoma is even rarer in gynecologic oncology practice and accounts for approximately only 1% of extranodal lymphomas.
  • In this article, two cases of cervical lymphoma are presented with a review of the available literature.
  • Radiological evaluation revealed a cervical mass with a 3 cm diameter.
  • Histopathological evaluation of LEEP material was reported as diffuse large B cell lymphoma.
  • We performed abdominal hysterectomy plus bilateral salphingo-oopherectomy and the patient was treated with adjuvant 6 cycles of CHOP chemotherapy.
  • Due to discordance between cytology and histology, LEEP was performed under colposcopic examination, which revealed follicular lymphoma grade III.
  • This patient was treated with 6 cycles CHOP chemotherapy without any surgery.
  • CONCLUSION: Primary cervical lymphoma is a rare disorder.
  • Therefore, cervical lymphomas should be kept in mind in patients with cytological abnormalities.
  • [MeSH-major] Lymphoma / pathology. Uterine Cervical Neoplasms / pathology


5. Mahé Ma, Bourdin S, Le Pourhiet-Le Mevel A, Moreau P, Campion L, Hamidou M, Milpied N, Moreau A, Gaillard F, Harousseau JL, Cuillière JC: Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy. Int J Radiat Oncol Biol Phys; 2000 Jun 1;47(3):735-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage extended-field irradiation in follicular non-Hodgkin's lymphoma after failure of chemotherapy.
  • PURPOSE: To evaluate the efficacy of total abdominopelvic (TAI) and total body irradiation (TBI) in heavily pretreated follicular non-Hodgkin's lymphoma (NHL).
  • All had Stage III or IV, Class B, C, D NHL in the working formulation and failed after receiving 1-5 regimens of chemotherapy.
  • TAI was given at 20 Gy over a 3-week period.
  • TBI was delivered in two successive half-body irradiations of 15 Gy over a 2-week period with a 4-week interval between each.
  • Median survival was 62 months, 5-year and 10-year overall survival was 59% and 41%, and disease-free survival was 56% and 30%, respectively.
  • Grade III or IV toxicity was gastrointestinal in 38% of patients and hematologic in 30%.
  • CONCLUSION: Extended-field irradiation is feasible and efficient after failure of chemotherapy in follicular NHL.
  • [MeSH-major] Lymphoma, Follicular / radiotherapy. Whole-Body Irradiation
  • [MeSH-minor] Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Radiotherapy Dosage. Salvage Therapy. Survival Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10837958.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


6. Forstpointner R, Hänel A, Repp R, Hermann S, Metzner B, Pott C, Hartmann F, Rothmann F, Böck HP, Wandt H, Unterhalt M, Hiddemann W: [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group]. Dtsch Med Wochenschr; 2002 Oct 25;127(43):2253-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Increased response rate with rituximab in relapsed and refractory follicular and mantle cell lymphomas -- results of a prospective randomized study of the German Low-Grade Lymphoma Study Group].
  • [Transliterated title] Rituximab zur Remissionsinduktion bei rezidivierten und refraktären indolenten Lymphomen und Mantelzell-Lymphomen - Ergebnisse einer prospektiv randomisierten Studie der deutschen Studiengruppe für niedrig maligne Lymphome (GLSG) -
  • BACKGROUND AND OBJECTIVE: Rituximab has shown a high activity in relapsed follicular lymphomas when given alone.
  • Further on, phase-II-studies indicate that its addition to chemotherapy may improve the response rate substantially.
  • PATIENTS AND METHODS: In 1998 the GLSG started a multicenter trial in patients with relapsed or refractory indolent lymphoma or mantle cell lymphoma.
  • A fludarabine-containing regimen (FCM) was chosen for salvage therapy, with fludarabine 25 mg/m(2)/d 1-3, cyclophosphamide 200 mg/m(2) d 1-3 and mitoxantrone 8 mg/m(2) d 1.
  • Patients were prospectively randomized for FCM alone or the immunochemotherapy with R-FCM (375 mg/m(2) one day before FCM) RESULTS: About 147 randomized patients 93 had follicular, 40 mantle cell and 14 lymphoplasmocytic/-cytoid lymphoma.
  • Similar improvements of remission rate were detected in the different lymphoma subgroups, especially in MCL (OR: 65 % vs. 33 %).
  • Both treatment options were associated with hematological toxicities of grade III and IV, but well tolerated; infectious complications were rare, with no difference between the two treatment groups.
  • CONCLUSION: This prospectively randomized trial demonstrates for the first time a significant improvement of the combined immunochemotherapy related to the remission rate in patients with relapsed or refractory indolent lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / drug therapy. Lymphoma, Mantle-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Vidarabine / analogs & derivatives
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Antimetabolites / administration & dosage. Combined Modality Therapy. Female. Humans. Immunosuppressive Agents / administration & dosage. Immunotherapy. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Male. Middle Aged. Mitoxantrone / administration & dosage. Recurrence. Remission Induction. Retrospective Studies. Rituximab. Time Factors

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12397539.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antimetabolites; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 4F4X42SYQ6 / Rituximab; BZ114NVM5P / Mitoxantrone; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


7. Ascaso FJ, Torres M, Bergua JM, Alvarez R, Cristóbal JA: Progressive external ophthalmoplegia: a paraneoplastic manifestation of lymphoma. Eur J Ophthalmol; 2002 Jul-Aug;12(4):315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progressive external ophthalmoplegia: a paraneoplastic manifestation of lymphoma.
  • To our knowledge, a syndrome mimicking progressive external ophthalmoplegia had never been reported preceding the diagnosis of a lymphoma.
  • CASE REPORT: A 63-year-old man developed progressive external ophthalmoplegia, without any other neurological symptoms, as the initial manifestation of a follicular lymphoma grade III.
  • The ophthalmoplegia resolved after two cycles of combination chemotherapy.
  • CONCLUSIONS: The ophthalmologist, when confronted with a progressive external ophthalmoplegia, should consider a neurological paraneoplastic syndrome associated with a tumor as a possible diagnosis.
  • [MeSH-major] Lymphoma, Follicular / complications. Ophthalmoplegia, Chronic Progressive External / etiology. Paraneoplastic Syndromes / etiology
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Cyclophosphamide / therapeutic use. Doxorubicin / analogs & derivatives. Doxorubicin / therapeutic use. Humans. Lymph Nodes / metabolism. Lymph Nodes / pathology. Male. Prednisone / therapeutic use. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12220003.001).
  • [ISSN] 1120-6721
  • [Journal-full-title] European journal of ophthalmology
  • [ISO-abbreviation] Eur J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol, modified
  •  go-up   go-down


8. Koenigsmann M, Knauf W, Herold M, Pasold R, Müller G, Eschenburg H, Kahl C, Lakner V, Assmann M, Jentsch-Ullrich K, Mohren M, Bartsch R, Franke A: Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO). Leuk Lymphoma; 2004 Sep;45(9):1821-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fludarabine and bendamustine in refractory and relapsed indolent lymphoma--a multicenter phase I/II Trial of the east german society of hematology and oncology (OSHO).
  • The therapy of patients with relapsed or refractory indolent lymphoma relies on the development of new drug combinations.
  • The drugs bendamustine and fludarabine have cytotoxic activity as monotherapy in indolent lymphoma and show synergism in vitro.
  • In this study, we combined both drugs in a multicenter clinical phase I/II trial to evaluate their toxicity and efficacy.
  • Bendamustine was given at 30 or 40 mg/m2/d (dose levels 1 and 2), fludarabine at 30 mg/m2/d, each drug on days 1 to 3.
  • A total of 29 patients with relapsed or refractory indolent lymphoma were included in the study.
  • Fourteen patients had follicular lymphoma, 11 patients mantle cell lymphoma, 2 patients lymphoplasmocytic and 2 patients nodal marginal zone lymphoma.
  • All patients were in stages III or IV of their disease and had received prior chemotherapy with or without additional radio- or immunotherapy.
  • The dose limiting toxicity was hematotoxicity in all cases and occurred in 3 of 7 evaluable patients at dose level I and in 3 of 7 patients at dose level 2.
  • Analysis of 19 evaluable patients treated at dose level 1 reveiled hematotoxicity CTC grade III in 47% and grade IV in 26%.
  • Nine of 9 patients with mantle cell lymphoma responded to therapy.
  • Eight of 15 responders relapsed after a median follow-up time of 14 months (range 2-43).
  • Dose level 1 with 30 mg/m2/d of both drugs on days 1 to 3 was defined as the recommended dose.
  • Despite unfavorable prognostic features (histologic subtype, stage of disease, pretreatment) response rates were good with this regimen.
  • [MeSH-major] Hematology. Lymphoma / drug therapy. Lymphoma / pathology. Medical Oncology. Nitrogen Mustard Compounds / therapeutic use. Societies, Medical. Vidarabine / analogs & derivatives. Vidarabine / therapeutic use
  • [MeSH-minor] Adult. Aged. Bendamustine Hydrochloride. Female. Germany. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Remission Induction. Time Factors

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. Bendamustine .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 Taylor and Francis Ltd
  • (PMID = 15223642.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Nitrogen Mustard Compounds; 981Y8SX18M / Bendamustine Hydrochloride; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


9. Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E, Trümper L, Brugger W, Ostermann H, Atzpodien J, Hallek M, Aulitzky E, Hiddemann W: IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol; 2000 Sep;79(9):493-500
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group.
  • PURPOSE: The current study was initiated to assess the clinical efficacy and side effects of rituximab in patients with relapsed advanced stage follicular lymphoma.
  • PATIENTS AND METHODS: The study was performed as an open-label non-randomized multicenter phase-II trial and included patients older than 18 years of age with relapsed advanced-stage follicular lymphomas (FL) grades I and II, according to the REAL classification, or with centroblastic/centrocytic (CB/CC lymphomas according to the Kiel classification.
  • The median time between primary diagnosis and study entry was 4.6 years (range 0.9-14.7 years).
  • Twenty grade-III/IV side effects were considered to be related to treatment: lymphocytopenia (3), granalocytopenia (1), thrombocytopenia (2), fever (1), hyperglycermia (1), venous thrombosis (1), syncope (1), plasmatic coagulation disorder (1), shortness of breath (2), photosensitivity (1), cardiac failure (1), chills (1), sepsis (1), tumor lysis (1), anemia (1), and pharyngeal edema (1).
  • Eight patients were not eligible for assessment of response because of non-follicular subtypes of low-grade lymphomas (n =6) or early termination of therapy at the first infusion because of severe side effects (n =2).
  • From the 30 evaluable cases with follicular lymphomas, five patients achieved a complete remission (CR) (17%), nine patients a partial remission (PR) (30%), and two patients a minor response (MR) (7%).
  • The median time to treatment progression (TTP) was 201 days (range 64-293 days), with five patients experiencing long-lasting remissions of 214-293 days duration.
  • Bulky disease (P=0.058) and/or bone-mar row involvement (P=0.046) were associated with poor response.
  • CONCLUSION: This study confirms the moderate treatment-related toxicity and the high antilymphoma activity of rituximab in patients with relapsed follicular lymphoma.
  • Further studies are needed to determine the role of rituximab in the first-line treatment of these disorders and its combination with conventional chemotherapy.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal, Murine-Derived. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recurrence. Rituximab. Treatment Outcome

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11043420.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] GERMANY
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down






Advertisement